Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nabpaclitaxel in patients with recurrent platinum-resistant ovarian cancer

Category Primary study
ConferenceJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 0967f9ce5c2f3d9179ead0f04442a543012cdbe3
First added on: Feb 14, 2025